IRCT20130603013572N8招募中Unknown
Bioequivalence study of two injectable sustained release formulations of Triptorelin (Decatrip® and Dipherelin®) in Patients with prostate cancer
Pooyesh Darou Biopharmaceuticals company0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 65 years（—）
- 性别
- Male
入选标准
- •Patients with Prostate Cancer
- •Availability of the patient for the entire study period and show willingness to adhere to study requirements
- •Able to give written consent
排除标准
- •History of hypersensitivity to the study drug
- •History of previous chemotherapy
- •Renal (serum creatinine twice normal) and hepatic failure (AST and ALT three times normal)
- •Administration of corticosteroids except for topical use
- •Donation of blood or plasma thirty days before the first day of this study
- •Vaccination one month before the first day of the study
- •Participation in a clinical trial one month before the first day of the study
研究者
相似试验
招募中
不适用
Bioequivalence Study of Injectable Extended-Release Naltrexone (380 mg) of Nano Daru pharma Co. (Exopio®) and Vivitrol® (as a reference) in Iranian Healthy volunteersIRCT20130603013572N4ano Daru pharmaceutical Co.48
已完成
不适用
bioequivalence of febuxostatIRCT20200705048005N1ChemiDaru Pharmaceutical Company26
招募中
2 期
Bioequivalence study of two Triptorelin vials manufactured by Ronak Darou and IPSEN in patients with prostate cancerMetastatic prostate cancer.Malignant neoplasm of prostateIRCT2016090410178N10Shahid Beheshti University of Medical Sciences50
已完成
Unknown
Comparative bioequivalence study of the extended release tamsulosin hydrochloride 0.4 mg tablet manufactured by Tasnim CompanyBioequivalence study in healthy volunteers.IRCT20130313012810N19Tasnim pharmaceutical Company24
招募中
1 期
Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy SubjectsDiabetesNCT05719961Jiangsu HengRui Medicine Co., Ltd.60